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Summary A cohort of 5072 patients with pernicious anaemia was identified in the Danish Hospital Discharge
Register from 1977 to 1989 and, through linkage to the Danish Cancer Registry, the occurrence of cancer in
the cohort was determined up to 1991. Observed numbers of cancer cases during 1- 15 years of follow-up were
compared with expected numbers based on national incidence rates. Besides the well-established increased risk
for stomach cancer, the analysis also revealed a 2-fold increase in the relative risk for cancer of the buccal
cavity and pharynx among pernicious anaemia patients in accordance with previous studies; previously
reported elevated risks for other digestive tract cancers were not confirmed. There was a non-significantly
increased risk for lymphatic and haematological malignancy but the risk tended to disappear after 5 years of
follow-up, indicating a possible selection bias. Decreased risks for cervical cancer and non-melanoma skin
cancer were also seen.
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Several previous studies have documented an increased
incidence of stomach cancer in patients with pernicious
anaemia (PA) (Blackburn et al., 1968; Elsborg and Mosbech,
1979; Borch et al., 1988; Brinton et al., 1989; Hsing et al.,
1993). An increase in the risk for other upper gastrointestinal
cancers such as buccal cavity and pharynx (Brinton et al.,
1989; Hsing et al., 1993) and oesophagus (Hsing et al., 1993)
has also been reported, as well as increases for other digestive
organ cancers [liver, biliary tract and pancreas (Hsing et al.,
1993)], though these cancers have been investigated less
extensively among PA patients than stomach cancer. Of
possible relevance to the autoimmune process in PA, studies
in the US (Brinton et al., 1989) and Sweden (Hsing et al.,
1993) have also reported increased risks for multiple
myeloma and myeloid leukaemia. We have performed a
linkage study similar in size to the large US and Swedish
studies between the nationwide Hospital Discharge and
Cancer Registries in Denmark in order to clarify further
the risk for gastrointestinal and other cancers among patients
with PA.
Materials and methods
Since 1977 the Hospital Discharge Register has kept records
of more than 99% of all discharges from non-psychiatric
hospitals in Denmark (Danish National Board of Health,
1981). For each discharge the register includes a personal
identification number unique to every Danish citizen, date of
discharge, up to 20 discharge diagnoses coded according to a
modified version of ICD-8 (Danish National Board of
Health, 1976) and codes for surgical procedures carried out
during the hospitalisation (Danish National Board of Health,
1973). All 6194 patients with ICD-8 codes 281.00-09 notified
in the Hospital Discharge Register during 1977-89 were
linked by the personal identification number to the Central
Population Register, whereby the personal number was
verified and dates of death or emigration were obtained. In
this process, 11 (0.2%) patients were excluded because either
they were not Danish residents or had an invalid
identification number.
For each patient, all discharges before and after the first
discharge with PA were also identified from the register file to
provide a full hospitalisation history covering the period
1977-89. Detailed evaluation of the hospitalisation history
led to identification of43 (0.7%) patients who had undergone
resection of the stomach. Since this surgical procedure may
lead to deficiency of intrinsic factor and thereby to secondary
PA, these patients were excluded from the study. Follow-up
started one year after the first known hospital discharge
reporting PA and continued until date of death, date of
emigration or the end of December 1991, whichever came
first. Excluding the first year of follow-up meant that 1068
(17%) patients who died on or within one year from the PA
hospitalisation did not contribute any follow-up time and
they were not counted in the final study cohort of 5072
patients. Those patients with PA who subsequently developed
cancer were ascertained through the linkage to the Danish
Cancer Registry (Storm et al., 1994). The expected number of
cancers was calculated from accumulated person-years and
national incidence rates, sub-divided by sex, age and calendar
time in 5 year intervals. Statistical methods used were based
on the assumption that the observed number of cancer cases
follows a Poisson distribution. Confidence intervals for the
relative risk (RR), i.e. the ratio of observed to expected
cancers, were computed using exact Poisson limits when the
observed number of cases was less than 10; otherwise Byar's
approximation was used (Rothman and Boice, 1979).
Results
During the follow-up of 5072 PA patients, 25768 person-
years were accrued with a mean follow-up interval of 5.1
years (range 1 - 15 years). The mean age at entry to the study
was 71 years for men and 73 years for women. The majority
of patients were women (66%).
The overall number of neoplasms observed during 1-15
years of follow-up was in accordance with the expected
number (Table I). A two-fold excess of stomach cancer was
seen, including one patient with a carcinoid tumour. In
addition, there was a significant increase in the risk for cancer
of the buccal cavity and pharynx. Risks were increased
among both men and women for these cancers. The excess of
cancer of the buccal cavity and pharynx was not confined to
any specific subsite such as lip, tongue or salivary glands.
One patient with cancer of the mouth and one with cancer of
the tonsil had a diagnosis of alcoholism in the Hospital
Discharge Register before the cancer diagnosis. Women
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November 1995experienced a significantly increased risk for oesophageal
cancer whereas men experienced a reduced risk. The risk for
non-Hodgkin's lymphoma, multiple myeloma and non-
lymphocytic leukaemia was moderately but not significantly
increased. Significantly reduced risks were observed for
cervical cancer and non-melanoma skin cancer (Table I).
The elevated RRs for cancer of the stomach and buccal
cavity and pharynx were comparable in the two periods of
follow-up, 1-4 and 5-15 years (Table II). Excesses of non-
Hodgkin's lymphoma and non-lymphocytic leukaemia were
confined to the period 1-4 years of follow-up, whereas there
was a small excess of multiple myeloma during both early
and late follow-up.
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Discussion
In this cohort study of patients with PA we found a two-fold
increase in the risk for stomach cancer in accordance with
previous estimates (Blackburn et al., 1968; Brinton et al.,
1989; Hsing et al., 1993). Our finding of an excess of cancer
of the buccal cavity and pharynx is consistent with findings in
the two large US and Swedish studies (Brinton et al., 1989;
Hsing et al., 1993). We have no information on important
risk factors such as alcohol intake and smoking habits but
two cases of buccal cavity and pharynx cancer had mention
of alcoholism in the hospital record. There was, however, no
general excess of other alcohol- or tobacco-related cancers in
Table 1 Observed (Obs) numbers and relative risks (RR) of cancer among patients with pernicious anaemia (PA) followed 1- 15 years after
the hospitalisation with PA
Both sexes Men Women
Cancer site Obs Expa RR 95% Clb Obs RR 95% CI Obs RR 95% CI
All malignant neoplasms 497 495.2 1.00 0.92-1.10 220 1.05 0.92-1.20 277 0.97 0.86-1.09
Buccal cavity and pharynx 16 8.0 2.0 1.1-3.3 8 1.8 0.8-3.5 8 2.3 1.0-4.5
Lip 2 2.4 0.8 0.1-3.1 0 - - 2 4.4 0.5-15.9
Tongue 2 1.0 2.0 0.2-7.3 1 2.7 0.1-15.0 1 1.6 0.0-9.0
Salivary glands 0 0.8 - - 0 - - 0 -
Mouth 7 2.4 2.9 1.2-6.0 3 3.1 0.6-9.2 4 2.8 0.8-7.1
Pharynx 5 1.5 3.4 1.1-7.9 4 4.5 1.2-11.4 1 1.7
Oesophagus 8 4.6 1.7 0.7-3.4 1 0.4 0.0-2.4 7 3.1 1.2-6.4
Stomach 50 21.2 2.4 1.7-3.1 26 2.7 1.7-3.9 24 2.1 1.3-3.1
Small intestine 2 1.3 1.5 0.2-5.5 1 1.8 0.0-10.0 1 1.3 0.0-7.3
Colon 50 52.6 1.0 0.7-1.3 17 1.0 0.6-1.5 33 1.0 0.7-1.3
Rectum 19 25.3 0.8 0.5-1.2 11 1.0 0.5-1.7 8 0.6 0.3-1.1
Liver 3 5.2 0.6 0.1-1.7 3 1.2 0.3-3.6 0 -
Gallbladder and biliary tract 6 6.6 0.9 0.3-2.0 3 2.0 0.4-5.8 3 0.6 0.1-1.7
Pancreas 19 17.2 1.1 0.7-1.7 7 1.1 0.4-2.3 12 1.1 0.6- 1.9
Lung 45 49.4 0.9 0.7-1.2 28 0.9 0.6-1.3 17 1.0 0.6- 1.6
Breast 39 48.4 0.8 0.6-1.1 1 2.9 0.1-16.1 38 0.8 0.6- 1.1
Cervix uteri 1 5.9 0.2 0.0-0.9 - - - 1 0.2 0.0-0.9
Corpus uteri 10 10.4 1.0 0.5-1.8 - 10 1.0 0.5-1.8
Ovary 6 10.0 0.6 0.2-1.3 - -- 6 0.6 0.2- 1.3
Prostate 39 33.4 1.2 0.8-1.6 39 1.2 0.8-1.6 - -
Kidney 14 12.7 1.1 0.6-1.8 6 1.1 0.4-2.3 8 1.1 0.5-2.2
Urinary bladder 23 28.1 0.8 0.5-1.2 16 0.9 0.5-1.4 7 0.7 0.3-1.5
Melanoma 4 6.9 0.6 0.2-1.5 1 0.4 0.0-2.5 3 0.7 0.1 -1.9
Non-melanoma skin cancer 57 74.4 0.8 0.6-1.0 19 0.6 0.4-1.0 38 0.9 0.6-1.2
Brain and nervous system 7 6.7 1.0 0.4-2.2 3 1.3 0.3-3.8 4 0.9 0.2-2.3
Lymphatic and haematological 35 28.4 1.2 0.9-1.7 15 1.2 0.7-2.0 20 1.2 0.8-1.9
Non-Hodgkin's lymphoma 14 9.6 1.5 0.8-2.5 3 0.8 0.2-2.4 11 1.9 0.9-3.3
Multiple myeloma 7 5.3 1.3 0.5-2.7 3 1.3 0.3-3.8 4 1.3 0.4-3.4
Leukaemia 13 12.5 1.0 0.6-1.8 8 1.4 0.6-2.8 5 0.7 0.2-1.7
Non-lymphocytic leukaemiac gd 5.2 1.7 0.8-3.3 4 1.8 0.5-4.6 5 1.7 0.6-4.0
Other specified sites 26 21.7 1.2 0.8-1.8 8 0.9 0.4-1.8 18 1.4 0.8-2.2
Secondary and unspecified sites 18 17.9 1.1 0.6-1.7 7 1.2 0.5-2.5 11 1.0 0.5-1.8
a Expected numbers of cancer. b Confidence interval. cNon-lymphocytic leukaemia includes chronic and acute myeloid leukaemia, monocytic
leukaemia and erythroleukaemia. d Three cases ofchronic myeloid leukaemia and six cases ofacute myeloid leukaemia.
Table II Observed (Obs) numbers and relative risks (RR) of cancer for selected sites according to length of follow-up among patients with
pernicious anaemia (PA)
Length offollow-up (years)
1-4 5-15
Person-years 15429 10339
Cancer site Obs RR 95% CP Obs RR 95% CI
Buccal cavity and pharynx 10 2.1 1.0-3.8 6 1.9 0.7-4.2
Lip 2 1.4 0.2-4.9 0 -
Tongue 1 1.7 0.0-9.4 1 2.5 0.1-14.0
Salivary glands 0 - 0 - -
Mouth 5 3.5 1.1-8.1 2 2.1 0.3-7.7
Pharynx 2 2.2 0.3-8.1 3 5.1 1.1 15.0
Stomach 32 2.4 1.6-3.3 18 2.4 1.4-3.7
Cervix uteri 1 0.3 0.0-1.6 0
Non-melanoma skin cancer 39 0.9 0.6-1.2 18 0.6 0.3-0.9
Lymphatic and haematological cancers 25 1.5 1.0-2.2 10 0.9 0.4-1.6
Non-Hodgkin's lymphoma 11 2.0 1.0-3.6 3 0.7 0.2-2.2
Multiple myeloma 4 1.3 0.3-3.2 3 1.4 0.3-4.2
Non-lymphocytic leukaemia 7 2.2 0.9-4.6 2 1.0 0.1-3.6
a Confidence interval.Peniko m ad caner
go L _Mere et a
1000
the cohort to suggest that alcohol or tobacco were not
important confounders.
Megaloblastic transformation owing to cobalamin defi-
ciency in PA which includes chromosomal changes, is
particularly seen in blood cell lines but may also occur in
the epithelial cells ofthe gastrointestinal tract (Babior, 1990).
Such changes, however, are not reflected in excess risks of
small intestine and haematopoietic cancers comparable to
those of buccal cavity, pharynx and stomach cancers. Risks
for some lymphatic and haematological cancers were
increased but not significantly as in previous investigations
(Brinton et al., 1989; Hsing et al., 1993). The reason for the
difference between results may be that we, in contrast to the
previous studies, excluded the first year of follow-up, where
there was an accumulation of non-Hodgkin's lymphoma,
multiple myeloma and myeloid leukaemia in our study. This
is parallel to observations for multiple myeloma and myeloid
leukaemia in the Swedish study (AW Hsing, personal
communication) and for myeloid leukaemia in the US study
(Brinton et al., 1989). In our opinion, the initial excess of
cases is probably due to inclusion of misdiagnosed
haematopoietic cancer in the PA cohort and does not reflect
a genuine association. Our analysis revealed a deficit of
cervical cancer and non-melanoma skin cancer; the latter
predominantly among men. These findings may be due to
chance although the reduced risk for the non-melanoma is
consistent with results from the Swedish study (Hsing et al.,
1993).
Acknowledgements
We thank Joseph K McLaughlin and Joseph F Fraumeni Jr for
useful comments on the manuscript and Andrea Bautz for
programming support. We also thank the National Board of
Health for access to data from the Hospital Discharge Register.
This study was supported by MAO NOI-CP-85639-04 from the
National Cancer Institute, Bethesda, Maryland, USA.
References
BABIOR BM. (1990). The megaloblastic anemias. In Hematology,
Williams WJ, Beutler E, Erslev AJ and Lichtman MA. (eds) pp.
453-481. McGraw-Hill: New York.
BLACKBURN EK, CALLENDER ST, DACIE JV, DOLL R, GIRDWOOD
RH, MOLLIN DL, SARACCI R, STAFFORD JL, THOMPSON RB,
VARADI S AND WETHERLEY-MEIN G. (1968). Possible associa-
tion between pernicious anaemia and leukaemia: a prospective
study of 1,625 patients with a note on the very high incidence of
stomach cancer. Int. J. Cancer, 3, 163- 170.
BORCH K, KULLMAN E, HALLHAGEN S, LEDIN T AND IHSE I.
(1988). Increased incidence ofpancreatic neoplasia in pernicious
anemia. World. J. Surg., 12, 866-870.
BRINTON LA, GRIDLEY G, HRUBEC Z, HOOVER R AND FRAUME-
NI JF JR. (1989). Cancer risk following pernicious anaemia. Br. J.
Cancer, 59, 810-813.
DANISH NATIONAL BOARD OF HEALTH. (1973). Classification of
Surgical Procedures and Therapies. (in Danish). Danish National
Board of Health: Copenhagen.
DANISH NATIONAL BOARD OF HEALTH. (1976). Classification of
Diseases. (in Danish). Danish National Board of Health:
Copenhagen.
DANISH NATIONAL BOARD OF HEALTH. (1981). The Activity in the
Hospital Care System. (in Danish). Danish National Board of
Health: Copenhagen.
ELSBORG L AND MOSBECH J. (1979). Pernicious anaemia as a risk
factor in gastric cancer. Acta Med. Scand., 206, 315-318.
HSING AW, HANSSON LE, MCLAUGHLIN JK, NYREN 0, BLOT WJ,
EKBOM A AND FRAUMENI JF JR. (1993). Pernicious anemia and
subsequent cancer. A population-based cohort study. Cancer, 71,
745-750.
ROTHMAN KJ AND BOICE JD. (1979). Epidemiologic Analysis with a
Programmable Calculator. DHHS Publication No (NIH) 79-
1649). US Government Printing Office: Washington DC.
STORM HH, MANDERS TAND LECKERS S. (1994). Cancer Incidence
in Denmark 1991. Danish Cancer Society: Copenhagen.